GeneVentiv Receives Orphan Drug Designation (ODD) for GENV-HEM for the Treatment of Hemophilia A or B with or without Inhibitors
RALEIGH, N.C., Nov. 2, 2021 /PRNewswire/ — GeneVentiv Therapeutics, a pre-clinical gene therapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to GENV-HEM for the treatment of Hemophilia A or B with or without…
Comments Off on GeneVentiv Receives Orphan Drug Designation (ODD) for GENV-HEM for the Treatment of Hemophilia A or B with or without Inhibitors